We also uncovered significant sex bias in transcription factor targeting of oncogenes and tumor suppressor genes, including AKT2 and KRAS that suggests lung cancer drugs targeting these genes might exhibit differences between the sexes in both efficacy and toxicity. Here, KRAS is linked to lung carcinoma.